AUKERA THERAPEUTICS
Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel.
AUKERA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Total Employee:
1+
Status:
Active
Total Funding:
650 K CHF
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellinta
Cellinta Limited is a biotechnology company that develops cancer-identifying technology with help of gene therapy for ant-cancer payloads.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Oncos Therapeutics
Oncos Therapeutics is a biotech company developing cancer therapies based on its next generation oncolytic viruses.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Venture Kick
Venture Kick investment in Grant - Aukera Therapeutics
BaseLaunch
BaseLaunch investment in Pre Seed Round - Aukera Therapeutics
More informations about "Aukera Therapeutics"
Aukera Therapeutics
Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology We develop first-in-class fully selective mTORC1 …See details»
Aukera, Inc. – Safe and Effective Delivery of …
Aukera, Inc. is a private biotechnology company that has developed a novel vault protein nanocapsule platform to safely and effectively deliver bioactive and biostimulatory molecules.See details»
Aukera Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Aukera Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Aukera Therapeutics GmbH - Venture Kick
Jun 5, 2025 Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology. We specialize in leveraging protein design to drive drug discovery on complex …See details»
AUKERA | Delivering solutions for the energy transition
As highly experienced developers and operators of renewable energy assets, Aukera has the expertise needed to support a project throughout its lifetime. We have more than a decade of experience in developing and operating onshore …See details»
Aukera Therapeutics GmbH - Swiss Biotech
Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR …See details»
Aukera Therapeutics GmbH - startup.ch
Aukera Therapeutics GmbH: Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology. We specialize in leveraging protein design to drive drug …See details»
Thomas Collet, PhD - Chemical Angel Network | LinkedIn
Mentor MIT $100K Entrepreneurship Competition 2009 - 20101 year Science and Technology Mentor Aukera Therapeutics, winner life sciences trackSee details»
Aukera Therapeutics GmbH - Venture Kick
Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel. Our discovery engine enables the development of new classes of pharmaceutical drugs to selectively target …See details»
DNASU Plasmid | User Registration
A repository of over 200,000 plasmids including Protein Structure Initiative protein expression plasmids and vectors, over 75,000 human plasmids, and whole genome collections from many …See details»
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in ...
4 days ago Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization Akebia Therapeutics, Inc. - GlobeNewswire - Mon Aug 4, 7:00AM …See details»
Aukera Therapeutics - LinkedIn
Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology. We specialize in leveraging protein design to …See details»
Aukera Therapeutics - Crunchbase Company Profile & Funding
Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera …See details»
Aukera Therapeutics qualifies for BaseLaunch funding program
Feb 18, 2022 The spin-off Aukera Therapeutics, which was founded at the Biozentrum last year, has been selected for the start-up accelerator program BaseLaunch. The biotech company …See details»
Aukera Therapeutics Named 2010 MIT Business Plan Contest
Cambridge, MA - Aukera Therapeutics has been named the 2010 MIT $100K Entrepreneurship Competition Life Sciences Track Winner. Aukera also won the Audience Choice Award, based …See details»
Aukera Therapeutics joins BaseLaunch Portfolio
Feb 15, 2022 Aukera Therapeutics joins BaseLaunch Portfolio We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 …See details»
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in ...
3 days ago Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 …See details»
Aukera Therapeutics - VentureRadar
Aukera Therapeutics was founded in 2021 by Dr. Stefan Imseng and Dr. Dritan Liko based on an Innosuisse-funded feasibility study. The spin-off from the Biozentrum possesses pioneering …See details»
Venture Kick support for Biozentrum spin-off Aukera Therapeutics
Oct 19, 2022 The start-up Aukera Therapeutics, founded at the Biozentrum of the University of Basel in 2021, has received funding of 150,000 Swiss francs from the Venture Kick initiative. …See details»
Aukera Therapeutics | VentureRadar
Aukera Therapeutics is a spin-off from the Biozentrum (University of Basel) and emerged from seminal research on mTOR biology. Aukera combines a deep understanding of cellular …See details»